한미사이언스
Not investment advice · For research purposes only; not a solicitation or an offer of any financial product. Past statistics do not indicate future outcomes. Facts from filings and public sources; not investment advice. No valuation estimate, direction or trading levels are provided.
① Fact table
Values as filed · consolidated / separate basis per year · no interpretation
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | KRW 950.2bn | KRW 1.0tn | KRW 1.2tn | KRW 1.3tn | KRW 1.4tn | KRW |
| Operating income | KRW 58.9bn | KRW 67.6bn | KRW 124.5bn | KRW 98.9bn | KRW 138.7bn | KRW |
| Net income | KRW 42.9bn | KRW 69.2bn | KRW 115.1bn | KRW 59.4bn | KRW 118.4bn | KRW |
| Total equity | KRW 690.3bn | KRW 724.7bn | KRW 787.5bn | KRW 840.9bn | KRW 961.9bn | KRW |
| Total liabilities | KRW 259.6bn | KRW 384.9bn | KRW 438.7bn | KRW 510.4bn | KRW 529.9bn | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준)· in house | 37.61 | 53.11 | 55.71 | 60.69 | 55.09 | % |
| Statement basis | Consolidated | Consolidated | Consolidated | Consolidated | Consolidated |
Show raw values
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | Unit |
|---|---|---|---|---|---|---|
| Revenue | 950,164,817,343 | 1,046,054,210,838 | 1,247,906,379,068 | 1,283,432,295,647 | 1,356,957,532,846 | KRW |
| Operating income | 58,852,290,702 | 67,626,014,492 | 124,468,680,998 | 98,867,912,225 | 138,727,168,534 | KRW |
| Net income | 42,939,923,264 | 69,209,578,706 | 115,121,512,760 | 59,421,641,043 | 118,369,957,151 | KRW |
| Total equity | 690,298,132,532 | 724,746,193,167 | 787,506,950,826 | 840,928,986,273 | 961,852,859,665 | KRW |
| Total liabilities | 259,599,611,967 | 384,942,964,397 | 438,697,577,009 | 510,375,220,087 | 529,854,025,529 | KRW |
| 부채비율(자체 계산: 부채총계 ÷ 자본총계 × 100, 자본 0 이하면 비움, 같은 해 같은 기준) | 37.61 | 53.11 | 55.71 | 60.69 | 55.09 | % |
Source: dart_fnltt · Computed in house · card as of 2026-10-13 · Filing date per year: not on the card (see the filing timeline below) · 'in house' marks items computed from the values above
② Profitability breakdown
Arithmetic on the fact table only · same year, same basis · '—' where a value is missing or the denominator is 0 or below · in each panel the bar height maps the span from the most negative to the largest positive value onto the panel height · no interpretation attached
Source: computed in house from the fact table · card as of 2026-10-13
③ My own calculation
A simple residual-income formula. You enter the assumptions; only the base equity is filled in from the filing. The result is computed from your assumptions and is not a figure this site publishes.
V = B₀ + (ROE − r) × B₀ ÷ (1 + r − ω)
Fill in all four boxes to compute. The site fills in nothing but the base equity.
Computed in this browser only; nothing you type is sent or stored.
- Base close 2026-10-13
- 50,200
- 80%
- 46,738.03 ~ 54,738.08
- 90%
- 45,126.24 ~ 56,901.30
- Ledger row
- f8cdff4b…
Source: fsc_stock_price · published 2026-10-14T11:05:08+09:00 · No direction implied
No day scored yet — no basis for a hit rate.
- 2026-10-07Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) (에페오토인젝터주(에페글레나타이드) 식품의약품안전처 품목허가 승인) original ↗Source: dart_disclosure
- 2026-10-07Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-10-07Filing title as filed임원ㆍ주요주주특정증권등거래계획보고서 original ↗Source: dart_disclosure
- 2026-10-02Filing title as filed기업설명회(IR)개최(안내공시) original ↗Source: dart_disclosure
- 2026-09-30Filing title as filed지주회사의자회사탈퇴 original ↗Source: dart_disclosure
- 2026-09-29Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-09-29Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-09-23Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-09-23Filing title as filed임원ㆍ주요주주특정증권등거래계획보고서 original ↗Source: dart_disclosure
- 2026-09-11Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-09-01Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-09-01Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
- 2026-09-01Filing title as filed주식등의대량보유상황보고서(일반) original ↗Source: dart_disclosure
- 2026-08-26Filing title as filed[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항) (급성골수성백혈병(AML) 치료 항암신약 HM43239 기술이전 계약 체결) original ↗Source: dart_disclosure
- 2026-08-24Filing title as filed투자판단관련주요경영사항(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-08-21Filing title as filed[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-08-21Filing title as filed[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항) original ↗Source: dart_disclosure
- 2026-08-14Filing title as filed반기보고서 (2026.06) original ↗Source: dart_disclosure
- 2026-08-12Filing title as filed최대주주등소유주식변동신고서 original ↗Source: dart_disclosure
- 2026-08-12Filing title as filed임원ㆍ주요주주특정증권등소유상황보고서 original ↗Source: dart_disclosure
| Layer | Badge | n | Note |
|---|---|---|---|
| range | unknown | 0 | 80%·90% 범위의 전향 적중 기록(목표일 개장 전 박제 → 종가 공표 뒤 채점) |
| fair_value | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| direction | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| trade_levels | 제공 안 함 | 0 | 판별력 미확인 — 싣지 않음 |
| Valuation estimate | not provided | — | Not published: no demonstrated discriminative power |
| Direction (up or down) | not provided | — | Not published: no demonstrated discriminative power |
| Trading levels | not provided | — | Not published: no demonstrated discriminative power |
Why this?
Checking…